Rachel L Navarra, PhD - Publications

2010-2016 Pharmacology and physiology Drexel University College of Medicine, Philadelphia, PA, United States 
 2016- Cell biology and neuroscience Rowan University School of Osteopathic Medicine 

8/9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Waterhouse BD, Navarra RL. The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Brain Research. PMID 30179606 DOI: 10.1016/j.brainres.2018.08.032  0.48
2018 Navarra RL, Waterhouse BD. Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Brain Research. PMID 29935154 DOI: 10.1016/j.brainres.2018.06.027  0.48
2016 Navarra RL, Clark BD, Gargiulo AT, Waterhouse BD. Methylphenidate Enhances Early Stage Sensory Processing and Rodent Performance of a Visual Signal Detection Task. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 27910862 DOI: 10.1038/npp.2016.267  0.48
2013 Navarra RL, Clark BD, Zitnik GA, Waterhouse BD. Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Experimental and Clinical Psychopharmacology. 21: 363-74. PMID 24099357 DOI: 10.1037/A0033563  0.36
2010 Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, ... Navarra RL, et al. Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 107: 8457-62. PMID 20404172 DOI: 10.1073/Pnas.1000730107  0.36
2010 Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, et al. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. The Journal of Pharmacology and Experimental Therapeutics. 332: 190-201. PMID 19828876 DOI: 10.1124/jpet.109.157388  0.36
2009 Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut Mv, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, ... ... Navarra RL, et al. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters. 19: 5552-5. PMID 19720528 DOI: 10.1016/j.bmcl.2009.08.050  0.36
2009 Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of Pharmacology and Experimental Therapeutics. 331: 574-90. PMID 19661377 DOI: 10.1124/Jpet.109.155994  0.36
Low-probability matches
2011 Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology. 218: 635-47. PMID 21643676 DOI: 10.1007/s00213-011-2357-6  0.01
Hide low-probability matches.